Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease

European Journal of Medicinal Chemistry

Volumn 40, Issue 9, 2005, Pages 908-917

  Smith, Daniel T ^a   Shi, Riyi ^b   Borgens, Richard B ^b   McBride, Jennifer M ^b   Jackson, Kevin ^c   Byrn, Stephen R ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

4 Aminopyridine; 4 Aminopyridine derivatives; Demyelination; Double sucrose gap chamber; Potassium channel blocker; Spinal cord injury

Indexed keywords

4 AMINOPYRIDINE DERIVATIVE; 4 DIMETHYLAMINOPYRIDINE; N (4 PYRIDYL)ETHYLCARBAMATE; N (4 PYRIDYL)METHYLCARBAMATE; N (4 PYRIDYL)TERT BUTYLCARBAMATE; POTASSIUM CHANNEL BLOCKING AGENT; SUCROSE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERIVATIZATION; FUNCTIONAL ASSESSMENT; GUINEA PIG; IONIZATION CHAMBER; ISOLATION PROCEDURE; NERVE CONDUCTION; NONHUMAN; SPINAL CORD INJURY;

4-AMINOPYRIDINE; ANIMALS; CARBAMATES; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EVOKED POTENTIALS, SOMATOSENSORY; GUINEA PIGS; MOLECULAR STRUCTURE; NEURAL CONDUCTION; SPINAL CORD INJURIES;

EID: 25444503485     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2005.04.017     Document Type: Article

References (51)

1. R.B. Borgens Restoring Function to the Injured Human Spinal Cord (Monograph), Springer-Verlag 2003 Heidelburg
2. I. Wickelgren Science 297 2002 178
3. C.M. Armstrong, and A. Loboda Biophys. J. 81 2001 895
4. M. Crest, E. Beraud-Juven, and M. Gola Perspect. Drug Discov. Des. 15-16 1999 333
5. F.S.P. Chen, and D. Fedida Perspect. Drug Discov. Des. 15-16 1999 227
6. T. Baukrowitz, and G. Yellen Proc. Natl. Acad. Sci. USA 93 1996 13357
7. A.P. Southan, and D.G. Owen Br. J. Pharmacol. 122 1997 335
8. K.M. Giangiacomo, J. Gabriel, V. Fremont, and T.J. Mullmann Perspect. Drug Discov. Des. 15-16 1999 167
9. A.R. Blight, and J.A. Gruner J. Neurol. Sci. 82 1987 145
10. R.R. Hansebout, A.R. Blight, S. Fawcett, and K. Reddy J. Neurotrauma 10 1993 19
11. P.J. Potter, K.C. Hayes, J.T.C. Hsieh, G.A. Delaney, and J.L. Segal Spinal Cord 36 1998 147 155
12. P.J. Potter, D.C. Hayes, J.L. Segal, J.T.C. Hsieh, S.R. Brunneman, G.A. Selaney, D.S. Tierney, and D. Mason J. Neurotrauma 10 1998 837
13. J. Qiao, K.C. Hayes, J.T.C. Hsieh, P.J. Potter, and G.A. Delaney J. Neurotrauma 14 1997 135 149
14. J.L. Segal, and S.R. Brunnemann Pharmacotherapy 17 1997 415
15. K.C. Hayes Restor. Neurol. Neurosci. 6 1994 259 270
16. Acorda Therapeutics. Acorda Therapeutics Reports Results of Fampridine-SR Clinical Trials (Press Release). April 14, 2004.
17. E.F. Targ, and J.D. Kocsis Brain Res. 328 1985 358
18. K.C. Hayes, A.R. Blight, and P.J. Potter Paraplegia 31 1993 216
19. S.G. Waxman, and J.M. Ritchie Ann. Neurol. 33 1993 121
20. J.L. Segal, M.S. Pathak, and J.P. Hernandes Pharmacotherapy 19 1999 713
21. I. Grijalva, G. Guízar-Sahagún, G. Castañeda- Hernández, D. Mino, H. Maldonado-Julián, G. Vidal-Cantú, A. Ibarra, O. Serra, H. Salgado-Ceballos, and R. Arenas-Hernández Pharmacotherapy 23 2003 823
22. C.M. Stork Clin. Toxicol. 32 1994 583
23. M.A. van der Bruggen, B.M. Huisman, H. Beckerman, F.W. Bertelsmann, C.H. Polman, and G.F. Lankhorst J. Neurol. 248 2001 665
24. A.R. Blight, J.P. Toombs, M.S. Bauer, and W.R. Widmer J. Neurotrauma 8 1991 103
25. A.D. Hertog, P. Biessels, J. Van den Akker, S. Agoston, and A. Horn Eur. J. Pharmacol. 142 1987 115
26. J.R. Howe, and J.M. Ritchie J. Physiol. 433 1991 183
27. J.K. Hirsh, and F.N. Quandt J. Pharmacol. Exp. Ther. 267 1993 604
28. G.J. Stephens, J.C. Garratt, B. Robertson, and D.G. Owen J. Physiol. 477 1994 187
29. J.W. Wegener, A. Peiter, S.R. Sampson, and H. Nawrath J. Cardiovasc. Pharmacol. 32 1998 134
30. G.E. Kirsch, and T. Narahashi J. Pharmacol. Exp. Ther. 226 1983 174
31. A. Albert, R. Goldacre, and J. Phillips J. Chem. Soc. 1948 2240
32. P.K. Wagoner, and G.S. Oxford Biophys. J. 58 1990 1481
33. B. Robertson, and D.G. Owen Br. J. Pharmacol. 109 1993 725
34. N.A. Castle, S.R. Fadous, D.E. Logothetis, and G.K. Wang Mol. Pharmacol. 46 1994 1175
35. N.A. Castle, S.R. Fadous, D.E. Logothetis, and G.K. Wang Mol. Pharmacol. 45 1994 1242
36. R. Bouchard, and D. Fedida J. Pharmacol. Exp. Ther. 275 1995 864
37. H. Zhang, B. Zhu, J.-A. Yao, and G.-N. Tseng J. Pharmacol. Exp. Ther. 287 1998 332
38. A. Niño, and C. Muñoz-Caro Biophys. Chem. 91 2001 49
39. A. Niño, C. Muñoz-Caro, R. Carbó-Dorca, and X. Girońs Biophys. Chem. 104 2003 417
40. R. Shi, and A.R. Blight J. Neurophysiol. 76 1996 1572
41. J.M. Jensen, and R. Shi J. Neurophysiol. 90 2003 2334
42. R. Shi, and A.R. Blight Neuroscience 77 1997 553
43. Calculated using Advanced Chemistry Development (ACD/Labs) Software Solaris V4.67 (1994-2005 ACD/Labs) and reported on SciFinder Scholar.
44. S. Ghosh, A. Krishnan, P.K. Das, and S. Ramakrishnan J. Am. Chem. Soc. 125 2003 1602
45. T. Kato, Y. Yamamoto, and S. Takeda Yakugaku Zasshi 93 1973 1034
46. N.A. Meanwell, S.Y. Sit, J. Gao, H.S. Wong, O. Gao, D.R. St. Laurent, and N. Balasubramanian J. Org. Chem. 60 1995 1565
47. A.L. Kovalenko, Y.V. Serov, A.A. Nikonov, and I.V. Tselinskii Z. Org. Khim. 27 1991 2074
48. R. Shi, and R.B. Borgens J. Neurophysiol. 81 1999 2406
49. R.B. Borgens, R. Shi, and T.D. Bohner J. Exp. Biol. 205 2002 1
50. L.J. Moriarty, B.S. Duerstock, C.L. Bajaj, K. Lin, and R.B. Borgens J. Neurol. Sci. 155 1998 121
51. R. Shi, and J.D. Pryor Neuroscience 110 2002 765